期刊文献+

Inactivation of mammalian target of rapamycin (mTOR) by rapamycin in a murine model of lipopolysaccharide-induced acute lung injury 被引量:13

Inactivation of mammalian target of rapamycin (mTOR) by rapamycin in a murine model of lipopolysaccharide-induced acute lung injury
原文传递
导出
摘要 Background The mammalian target of rapamycin (mTOR) pathway, a key cellular signaling pathway associated with various cellular functions, has distinct roles in the inflammatory process. In this study, the mTOR inhibitor rapamycin (Rapa) was used to test whether inhibition of mTOR activation attenuates lipopolysaccharide (LPS)-induced acute lung injury (ALl) in a murine model.Methods Mice pretreated with Rapa or vehicle were given LPS intratracheally. Local cell numbers and inflammatory cytokines present in the bronchoalveolar lavage fluid (BAL), wet-to-dry weight ratio, histopathology of the lungs, and survival were evaluated.Results The phosphorylation of S6, a major downstream target of mTOR, had a 3-fold increase in lung tissue after LPS stimulation, but the increase was blocked by Rapa. Rapa reduced the levels of TNF-α (LPS vs. LPS + Rapa,(1672.74±193.73) vs. (539.17±140.48) pg/ml, respectively; P 〈0.01) and IL-6 (LPS vs. LPS + Rapa: (7790.88±1170.54)vs. (1968.57±474.62) pg/ml, respectively; P 〈0.01) in the BAL fluid. However, Rapa had limited effects on the overall severity of ALI, as determined by the wet-to-dry weight ratio of the lungs, number of neutrophils in the BAL fluid, and changes in histopathology. In addition, Rapa failed to reduce mortality in the LPS-induced ALI model.Conclusions We confirmed that mTOR was activated during LPS-induced ALI and strongly inhibited by Rapa.Although Rapa reduced the levels of the mediators of inflammation, the overall severity and survival of the ALI murine model were unchanged. Background The mammalian target of rapamycin (mTOR) pathway, a key cellular signaling pathway associated with various cellular functions, has distinct roles in the inflammatory process. In this study, the mTOR inhibitor rapamycin (Rapa) was used to test whether inhibition of mTOR activation attenuates lipopolysaccharide (LPS)-induced acute lung injury (ALl) in a murine model.Methods Mice pretreated with Rapa or vehicle were given LPS intratracheally. Local cell numbers and inflammatory cytokines present in the bronchoalveolar lavage fluid (BAL), wet-to-dry weight ratio, histopathology of the lungs, and survival were evaluated.Results The phosphorylation of S6, a major downstream target of mTOR, had a 3-fold increase in lung tissue after LPS stimulation, but the increase was blocked by Rapa. Rapa reduced the levels of TNF-α (LPS vs. LPS + Rapa,(1672.74±193.73) vs. (539.17±140.48) pg/ml, respectively; P 〈0.01) and IL-6 (LPS vs. LPS + Rapa: (7790.88±1170.54)vs. (1968.57±474.62) pg/ml, respectively; P 〈0.01) in the BAL fluid. However, Rapa had limited effects on the overall severity of ALI, as determined by the wet-to-dry weight ratio of the lungs, number of neutrophils in the BAL fluid, and changes in histopathology. In addition, Rapa failed to reduce mortality in the LPS-induced ALI model.Conclusions We confirmed that mTOR was activated during LPS-induced ALI and strongly inhibited by Rapa.Although Rapa reduced the levels of the mediators of inflammation, the overall severity and survival of the ALI murine model were unchanged.
出处 《Chinese Medical Journal》 SCIE CAS CSCD 2011年第19期3112-3117,共6页 中华医学杂志(英文版)
关键词 mammalian target of rapamycin complex 1 RAPAMYCIN acute lung injury LIPOPOLYSACCHARIDE mammalian target of rapamycin complex 1 rapamycin acute lung injury lipopolysaccharide
  • 相关文献

参考文献34

  • 1Ware LB,Matthay MA.The acute respiratory distress syndrome.N Engl J Med 2000; 342:1334-1349.
  • 2Vincent JL,Sakr Y,Ranieri VM.Epidemiology and outcome of acute respiratory failure in intensive care unit patients.Crit Care Med 2003; 31 (4 Suppl):S296-S299.
  • 3Hudson LD,Milberg JA,Anardi D,Maunder RJ.Clinical risks for development of the acute respiratory distress syndrome.Am J Respir Crit Care Med 1995; 151:293-301.
  • 4Arbour NC,Lorenz E,Schutte BC,Zabner J,Kline JN,Jones M,et al.TLR4 mutations are associated with endotoxin hyporesponsiveness in humans. Nat Genet 2000; 25:187-191.
  • 5Kline JN,Cowden JD,Hunninghake GW,Schutte BC,Watt JL, Wohlford-lenane CL, et al. Variable airway responsiveness to inhaled lipopolysaccharide.Am J Resp Crit Care Med 1999; 160:297-303.
  • 6Togbe D,Schnyder-Candrian S,Schnyder B,Doz E,Noulin N,Janot L,et al.Toll-like receptor and tumour necrosis factor dependent endotoxin-induced acute lung injury.Int J Exp Pathol 2007; 88:387-391.
  • 7Katso R,Okkenhaug K,Ahmadi K,White S,Timms J,Waterfield MD. Cellular function of phosphoinositide 3-kinases:implications for development,homeostasis,and cancer.Annu Rev Cell Dev Biol 2001; 17:615-675.
  • 8Deane JA,Fruman DA.Phosphoinositide 3-kinase:diverse roles in immune cell activation.Annu Rev Immunol 2004; 22:563-598.
  • 9Saemann MD,Haidinger M,Hecking M,Horl WH,Weichhart T.The multifunctional role of mTOR in innate immunity:implications for transplant immunity.Am J Transplant 2009:2655-2661.
  • 10Ko H,Hambly BD,Eris JM,Levidiotis V,Wybum K,Wu H,et al.Dentritic cell derived IL-18 production is inhibited by rapamycin and sanglifehrin A,but not cyclosporine A.Transpl Immunol 2008; 20:99-105.

同被引文献22

引证文献13

二级引证文献52

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部